Weill Cornell Medicine researchers have determined the full-length structure of a blood pressure-regulating hormone receptor for the first time, uncovering how it functions, which may enable better drug targeting of the receptor for diseases like hypertension and heart failure.
Weill Cornell Medicine Nov 15 2024
These new structural details will be of interest to drug developers who want to target GC-A and related receptors to treat heart disease and other conditions." Promising cardiovascular drug target GC-A is expressed in various tissues—including the kidneys, blood vessels, adrenal glands, lungs, intestines and brain. Its partner hormones are atrial natriuretic peptides, secreted by heart cells. When the atrial natriuretic hormone binds to GC-A, the receptor is activated and sends a signal to the interior of the cell where several pathways work to lower blood pressure.
The structure in focus The researchers identified the precise arrangements and interactions of the multiple functional domains of the receptor. They also determined the points where two copies of the receptor proteins are joined, which is necessary for binding its hormone partner. This allowed them to see how the segments upon receptor activation transmit signals within the cell.
Heart Disease Medicine Receptor Biochemistry Blood Blood Pressure Cell Cell Membrane Electron Electron Microscopy Heart Failure Hormone Membrane Microscopy Molecular Biology Physiology Protein
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Weill Cornell Medicine professor receives major grant for pediatric pain management studyDr. Chani Traube, the Gerald M. Loughlin, MD Professor of Pediatrics at Weill Cornell Medicine, has been awarded a $3.
Read more »
Weill Cornell Medicine teams receive funding from Starr Cancer ConsortiumThree teams led by Weill Cornell Medicine scientists have received awards from the Starr Cancer Consortium in its 17th and final annual grant competition.
Read more »
Study identifies biomarkers for immunotherapy success in liver cancerIt may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit from immunotherapy, according to a preclinical study by Weill Cornell Medicine investigators.
Read more »
Researchers discover how ovarian tumors cripple immune cellsWeill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack-;blocking the energy supply T cells depend on.
Read more »
New insights into melanoma metastasis reveal potential drug targetInvestigators from Weill Cornell Medicine have discovered a defense mechanism that protects skin cancer cells from oxidative stress and helps them spread.
Read more »
Virtual screening yields small molecules to enhance cancer immunotherapyThe process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine researchers.
Read more »